ALSO NOTED: Stem cell research backed by public; Graham critical of FDA safety plans; and much more...

> A new poll by Harris Interactive finds the majority of Americans favor federal funding for stem cell research. Story (Wall Street Journal sub. req.)

> The Wall Street Journal reports that venture capitalists want a change in the stem cell rules as well. Story (sub. req.)

> FDA drug safety expert David Graham is critical of the agency's new drug safety panel. Story

> Chutes & Ladders: Zix named Charles N. "Chip" Kahn III and Paul E. Schlosberg to its board of directors. Release

> AARP is throwing its weight behind Medicare Part D and working with UnitedHealth. Some critics are unhappy about that. Story

> UK-based consultancy Wireless Healthcare has released a special report titled "101 things to do with a Mobile Phone in Healthcare," which looks at cell phone use in the healthcare industry and potential applications. Report (pdf)

> ImClone's Erbitux does well in a major trial pitting it against head and throat cancers. Story

And Finally... The average family pays $922 in additional insurance premiums as a result of the uninsured problem, a study from Families USA finds. Story